iiinova — where your digital self keeps evolving

Latent Labs @latentlabs.bsky.social · 16/12/2025

Drug discovery has long been bottlenecked not by hits, but by development. Latent-X2 is our step toward designing the right molecule from the start. Technical report: tinyurl.com/latent-X2-re... Blog: www.latentlabs.com/latent-x2 Apply for access: partnerships@latentlabs.com

tinyurl.com

010

Latent Labs @latentlabs.bsky.social · 16/12/2025

To enable reproduction, we're publishing the sequences and structures of a lab-validated antibody design for each target — accessible on the Latent Labs Platform without sign-in.

120

Latent Labs @latentlabs.bsky.social · 16/12/2025

For the first time: immunogenicity assessment of an AI-generated antibody. De novo VHH binders cleared ex vivo assays across a ten-donor human panel. Combined with developability profiles matching approved therapeutics — drug-like from the first generation.

100

Latent Labs @latentlabs.bsky.social · 16/12/2025

Latent-X2 achieves picomolar to nanomolar affinities across VHH, scFv, and macrocyclic peptides — testing just 4-24 designs per experiment. Hits on K-Ras, long considered undruggable, matching trillion-scale screens while testing 11 orders of magnitude fewer sequences.

100

Latent Labs @latentlabs.bsky.social · 16/12/2025

5 months from Latent-X1 to Latent-X2. AI-generated antibodies with drug-like developability and low immunogenicity in human panels — zero-shot. Available now for selected partners.

132

Latent Labs @latentlabs.bsky.social · 16/12/2025

latentlabs.com

Latent X2 - Latent Labs

000

Latent Labs @latentlabs.bsky.social · 16/12/2025

To enable reproduction, we're publishing the sequences and structures of a lab-validated antibody design for each target — accessible on the Latent Labs Platform without sign-in.

100

Latent Labs @latentlabs.bsky.social · 16/12/2025

100

Latent Labs @latentlabs.bsky.social · 21/08/2025

The AWS partnership has been providing scalable compute through Amazon SageMaker HyperPod and an incredible community that's accelerated our mission.

100

Latent Labs @latentlabs.bsky.social · 21/08/2025

Instead of waiting weeks or months for lab experiments, researchers can now get to precision breakthrough molecules at the push of a button.

100

Latent Labs @latentlabs.bsky.social · 21/08/2025

Our Latent-X model uses AI to design proteins and model molecular interactions – moving beyond what nature gives us to precisely engineering what we need for therapeutics, food tech, and climate solutions.

100

Latent Labs @latentlabs.bsky.social · 21/08/2025

🧬 From observational science to engineering – this is the transformation we're driving in biology.

110

Latent Labs @latentlabs.bsky.social · 11/08/2025

Latent-X is available with a free tier on our platform now: platform.latentlabs.com

platform.latentlabs.com

Latent Labs - Beta

000

Latent Labs @latentlabs.bsky.social · 11/08/2025

Latent-X has been available for over two weeks and we couldn't be more excited about the science already being done with it. Our CEO @saakohl.bsky.social joined @bloomberg.com News Daybreak Europe today to talk why we're building it, and the impact it is having. Watch here: tinyurl.com/yjzyhr23

youtube.com

Nvidia, AMD to Pay US 15% of China AI Chip Sales; Trump-Putin Summit | Daybreak Europe 8/11/2025

YouTube video by Bloomberg Television

100

Latent Labs @latentlabs.bsky.social · 25/07/2025

🔬 Mini-binders represent a new therapeutic modality — for targeted delivery, diagnostics, and therapeutic inhibitors. For partnerships: partnerships@latentlabs.com

000

Latent Labs @latentlabs.bsky.social · 25/07/2025

🚀 Available now on the Latent Labs Platform with free tier access: * No-code interface * Upload targets, select epitopes, generate binders * 10x faster than previous methods * Computational ranking for lab prioritization

130

Latent Labs @latentlabs.bsky.social · 25/07/2025

🧪 Lab-validated target specificity across all tested mini-binders. See the all-against-all binding screen via our in-house mDisplay assay below:

100

Latent Labs @latentlabs.bsky.social · 25/07/2025

⚡ Watch Latent-X generate a picomolar mini-binders from scratch — solving the geometric puzzle of binding at the all-atom level in real-time. Every atom placed with precision to create the biochemistry required for tight, specific binding.

100

Latent Labs @latentlabs.bsky.social · 25/07/2025

🔬 Look at the generated non-covalent bonds — hydrogen bonds, pi-stacking, van der Waals interactions. Latent-X doesn't just predict binding; it generates the exact biochemical interactions needed for high affinity and specificity.

100

Latent Labs @latentlabs.bsky.social · 25/07/2025

🎯 Extensive lab validation shows leading performance: * 100% target success rate (5/5 therapeutically relevant proteins) * Picomolar binding affinities achieved * 10-64% experimental hit rates * Testing just ~100 designs per target vs millions traditionally

100

Latent Labs @latentlabs.bsky.social · 25/07/2025

🧬Latent-X is our first frontier model for protein design. For mini-binders, our AI model achieved picomolar binding affinities — the strongest reported vs prior methods in head-to-head lab validation. Explore our best binders here: platform.latentlabs.com More details on the breakthrough in this🧵

166

Latent Labs @latentlabs.bsky.social · 24/07/2025

In extensive wet lab experiments, Latent-X achieved what would typically require millions of candidates by testing as little as 30-100 candidates per target—yet achieved strong binding affinities down to the picomolar ranges. Sign-up for early access at: platform.latentlabs.com

platform.latentlabs.com

Latent Labs - Beta

000

Latent Labs @latentlabs.bsky.social · 24/07/2025

‘Latent Labs launches web-based AI model to democratize protein design.’ Thank you @techcrunch.com and Marina Temkin for the coverage. Read the full story: tinyurl.com/Latent-X-Tec...

tinyurl.com

Latent Labs launches web-based AI model to democratize protein design | TechCrunch

The company claims that its model achieved state of the art on specific metrics.

100

Latent Labs @latentlabs.bsky.social · 22/07/2025

Starting with macrocycles and mini-binders, expanding to nanobodies and more. Our mission: make biology programmable to make drug design instantaneous. Join early access: platform.latentlabs.com Technical report: tinyurl.com/latent-X Technical details: www.latentlabs.com/latent-x

011

Latent Labs @latentlabs.bsky.social · 22/07/2025

Latent-X solves the geometric puzzle of binding at the all-atom level, generating novel binders from scratch while obeying nature's biochemical rules. Scientists can now access lab-validated AI workflows without needing AI expertise or infrastructure.

111

Latent Labs @latentlabs.bsky.social · 22/07/2025

Traditional drug discovery screens millions of random molecules with <1% hit rates. Latent-X flips this: we generate 30-100 precise designs per target and achieve lab success rates up to 100%. The efficiency gains are dramatic.

100

Latent Labs @latentlabs.bsky.social · 22/07/2025

5 months from funding to shipping our first frontier model. Latent-X achieves state-of-the-art hit rates for macrocycles and mini-binders, with picomolar binding affinities — a breakthrough in de novo protein binder design. Available now on our no-code platform!

153

Latent Labs @latentlabs.bsky.social · 13/05/2025

Catch @saakohl.bsky.social's panel with Glen Gowers, Michael Curtis, Amber Salzman, and Oliver Barnes at the @financialtimes.com Biotech Summit this Thursday discussing what the future holds for AI-driven drug discovery.

100

Latent Labs @latentlabs.bsky.social · 06/05/2025

Read more about how we’re working with AWS to put AI directly into the hands of biologists, pharma, and biotech innovators around the world: shorturl.at/0t63L

latentlabs.com

Latent Labs and AWS announce collaboration to scale generative AI for the Life Sciences - Latent Labs

000

Latent Labs @latentlabs.bsky.social · 06/05/2025

Latent Labs is partnering with @awscloud.bsky.social to super‑charge generative AI for the life sciences. Together, we’ll scale access to protein design tools that help scientists discover breakthrough therapies faster.

120

Latent Labs @latentlabs.bsky.social · 13/02/2025

"Latent Labs is building AI foundation models to 'make biology programmable', partnering with biotech and pharma to generate and optimize proteins." Huge thanks to @techcrunch.com, our investors & supporters. Follow us as we push the frontiers of AI & biology. techcrunch.com/2025/02/12/f...

techcrunch.com

Founded by DeepMind alumnus, Latent Labs launches with $50M to make biology programmable | TechCrunch

A new startup from one of the key scientists at Google DeepMind exits stealth today with $50 million in funding.

341

Latent Labs @latentlabs.bsky.social · 13/02/2025

"What if scientists could create the building blocks of new medicines completely from scratch, targeting diseases with precisely designed cures?" Thank you @forbes.com & @davidprosser for the coverage: www.forbes.com/sites/davidp...

forbes.com

How Latent Labs Plans To Create Medicines From Scratch With AI

Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for drug discovery and development

010

Latent Labs @latentlabs.bsky.social · 13/02/2025

"One of DeepMind’s Nobel-prize winning AlphaFold team has raised $50 million to launch his own venture designing new proteins, with the goal of “achieving computational mastery over biology”." Thank you @thetimes.com and @richardtyler for featuring us: www.thetimes.com/business-mon...

thetimes.com

Google star raises $50 million to use AI to design proteins

Latent Labs founder Simon Kohl, a former member of the internet giant’s DeepMind team, has a new target

031

Latent Labs @latentlabs.bsky.social · 13/02/2025

"Simon Kohl, a scientist, has raised $50M to launch a startup to discover new drugs." We’re grateful for the incredible response to our mission. Thank you @financialtimes.com, @hannahkuchler.bsky.social & @melissahei.bsky.social. www.ft.com/content/9214...

ft.com

Ex-DeepMind scientist launches AI drug discovery venture

Simon Kohl aims to capitalise on his experience with Nobel-recognised AlphaFold protein prediction system

010

Reposted by Latent Labs

Simon Kohl @saakohl.bsky.social · 13/02/2025

I loved my time at DeepMind working on AlphaFold2 and to be there in Stockholm to watch Demis Hassabis and John Jumper accept the Nobel Prize was incredible.

121

Reposted by Latent Labs

Simon Kohl @saakohl.bsky.social · 13/02/2025

We’ve built an exceptional founding team – and are hiring in London and San Francisco! Come join the likes of Alex Bridgland (AlphaFold 1, 2 & 3), Annette Obika-Mbatha (multiple DeepMind programs), Dave Yuan (Mammoth Bio) and amazing people from Microsoft, Google, Altos Labs, Stability AI and more.

132

Reposted by Latent Labs

Simon Kohl @saakohl.bsky.social · 13/02/2025

Our Angels include Google Chief Scientist @jeffdean.bsky.social, Transformer architecture co-inventor and Cohere founder @aidangomez.bsky.social, and ElevenLabs founder Mati Staniszewski.

131

Reposted by Latent Labs

Simon Kohl @saakohl.bsky.social · 13/02/2025

The funding includes our Series A co-led by Radical Ventures and Sofinnova Partners, with existing investors Pillar VC, Kindred Capital and 8VC participating alongside new investors Isomer Capital and Flying Fish.

121

Reposted by Latent Labs

Simon Kohl @saakohl.bsky.social · 13/02/2025

Every biotech or pharma company searching for the best therapeutic molecules understands the role AI can play - but not all are in a position to develop their own advanced models. That’s where @latentlabs.bsky.social comes in.

131

Reposted by Latent Labs

Simon Kohl @saakohl.bsky.social · 13/02/2025

Apply to access our tools or join the team www.latentlabs.com

021

Reposted by Latent Labs

Simon Kohl @saakohl.bsky.social · 13/02/2025

It is clear protein design has the potential to transform medicine and scientific discovery. I believe Latent Labs will be the team to fully realize its potential. It’s a vast field and there’s so much still to do. Let’s go!

121

Latent Labs @latentlabs.bsky.social · 13/02/2025

We are out of stealth with $50M in funding. Join us on our moonshot mission of making biology programmable and reach out to work with us today.

051